# A Phase 3 Study of AGA111 in Patients With Degenerative Disc Disease Undergoing Lumbar Interbody Fusion

> **NCT06115512** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Angitia Biopharmaceuticals** · enrollment: 412 (actual)

## Conditions studied

- Degenerative Disc Disease

## Interventions

- **DRUG:** AGA111
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06115512
- **Lead sponsor:** Angitia Biopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-08
- **Primary completion:** 2025-11-28
- **Final completion:** 2026-11-30
- **Target enrollment:** 412 (ACTUAL)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06115512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06115512, "A Phase 3 Study of AGA111 in Patients With Degenerative Disc Disease Undergoing Lumbar Interbody Fusion". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06115512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*